Xipere patents expiration

XIPERE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8636713 BAUSCH AND LOMB INC Methods and devices for drug delivery to ocular tissue using microneedle
May, 2027

(3 years from now)

US9636332 BAUSCH AND LOMB INC Methods and devices for the treatment of ocular diseases in human subjects
Nov, 2033

(10 years from now)

US9937075 BAUSCH AND LOMB INC Apparatus and methods for ocular injection
May, 2034

(10 years from now)

Xipere is owned by Bausch And Lomb Inc.

Xipere contains Triamcinolone Acetonide.

Xipere has a total of 3 drug patents out of which 0 drug patents have expired.

Xipere was authorised for market use on 22 October, 2021.

Xipere is available in suspension;injection dosage forms.

Xipere can be used as treatment of macular edema associated with uveitis.

The generics of Xipere are possible to be released after 02 May, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 22, 2024

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 22 October, 2021

Treatment: Treatment of macular edema associated with uveitis


More Information on Dosage

XIPERE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic